RE:RE:RE:RE:RE:RE:RE:New presentation up - realistic review. How many people were emplyoyed before and after the decidion to have an in house sales organization and how many people were there before Dec 1 and now!! Is 165 now too high? I dont think we have the data to answer that question....I
qwerty22 wrote: Whatever structure was in place to expand into Ph2 in US and EU can certainly be dismantled now.
SPCEO1 wrote: I don't have an indication of how THTX employees break down by department but you could get a good idea by looking at LinkedIn. My point is Paul was building out the company based on premises that are no longer valid. In the new environment, THTX likely does not need to have as robust staffing as they thought they would earlier. Given the baggage from the convert, the sooner they make cost cuts where sensible the better. I have wondered to myself sometimes is the cost of sales have risen more than sales recently. It is great to have growing sales but but if it costs $1.20 to obtain a new $1in sales, that is not ideal, obviously.
palinc2000 wrote: Not sure why you think that 165 employees is too many,Do you have the breakdown by categories.We have been told that the cost of in house sales organization is not higher than outside contracting....The parachute for all of long term shareholders is growing sales...If they were to cancel the oncology platform all together then there will be some reduction in the number of employees but they need to reach a final determination as to wether or not the pause is temporary or for ever...Firing employees involved solely in that progtam now make no sense ...
I am more and more convinced that the Nash trial with a partner will occur ....They are very careful in their wording just in case things dont go as planned but the rabbit is there
1 am still frustrated when I see the balance remaining to be paid to the holders of the convert in just a few months ////They will find the money but will be left cash strapped /Opting for a Convert rather than stock issue 5 years ago has had the effect of putting a straight jacket on the company.....The company will get over it ....I will also .....eventually
SPCEO1 wrote: I was surprised to see in the presentation that there were still 165 employees at THTX. I would have thought the number would have moved down due to early cost-cutting and some employees moving on to other jobs. It looks like Paul's executive assistant has moved on as they are looking to fill that position.
While it is not much fun to look at a THTX corporate presentation with cancer at the end of it, it is a good presentation for what the company now looks like. The new data on the market sizes of Egrifta and Trogarzo is helpful and seems more reasonable that forecasts from years back. Hopefully, the indication that doctors may tie GILD's new drug together with Trogarzo is accurate as that could really help promote Trogarzo sales.
You are right that we are left with a growing legacy drug business selling very cheaply and two short term, low probability, wild cards in NASH and cancer. Since those wild cards are low probability, no one is paying up for them now but should either come to fruition, the stock would have a nice bounce. I think we will know the outcome of those wild cards in the next few months so we will not likely have to wait long to see if there is something there. I expect cancer to be effectively shelved for now but Egrifta has a chance of finally rewarding Dr. Grinspoon and THTX's many efforts to make it relevant in NASH on the back of the MDGL news.
SABBOBCAT wrote: They are doing what they can and have clearly highlighted the opportunities for partners. Essentially what it boils down to is, they have a plan to grow revenues and lean on the commercial side to try and get an appropriate valuation, but the only quick wins will come from securing partnerships.
So the investment thesis is, buy now with a path to growth and limited downside, plus a two free lottery tickets for your trouble.